glp-1 agonists marketing strategies 2025 Market Exclusive Research Report GLP-1 Receptor Agonist Market Size

Related: Who May Be at Higher Risk Higher-risk individuals may include: patients with prior GI disorders individuals prone to dehydration people with kidney disease patients with diabetes-related vascular disease older adults long-term GLP-1 users Saxenda and Lawsuits Saxenda is included in broader GLP-1 litigation , particularly claims involving: severe motility disorders kidney injury gallbladder surgery pancreatitis permanent digestive injury blindness / NAION Saxenda lawsuits hub: Lawsuits When to Consider a Review You may want to consider review if: you used Saxenda, AND you required ER care or hospitalization, OR you developed a diagnosed complication, OR symptoms persisted after stopping the drug Start here: File a Claim Saxenda is an established weight-loss GLP-1 medication that can help reduce appetite and body weight, but it may also cause serious and persistent side effects in some patients

Kim S-J, Nian C, Doudet DJ, McIntosh CH

Supporting this hypothesis, we demonstrate that GLP-1 receptor-mediated targeting of MK-801 effectively avoids other adverse effects associated with MK-801 monotherapy, including hyperthermia and hyperlocomotion

JAMA Health Forum 2 , e214182 (2021)

These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity